autoimmune disease

Lilly, Aduro Biotech in Immunotherapy Alliance
Lilly, Aduro Biotech in Immunotherapy Alliance
Contract Pharma
Eli Lilly
Aduro BioTech
autoimmune disease
drug development
Flag link:
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Flag link:
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
Endpoints
IPOs
Principia Biopharma
Sanofi
AbbVie
PRN1008
autoimmune disease
Flag link:
Bristol-Myers Squibb signs new development agreement for autoimmune disorders treatments
Bristol-Myers Squibb signs new development agreement for autoimmune disorders treatments
GoinPharma
autoimmune disease
Bristol-Myers Squibb
Flag link:
Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
Xconomy
Sangamo BioSciences
M&A
TxCell
autoimmune disease
cell therapy
Flag link:
Novartis touts effectiveness, safety of autoimmune drug copies
Novartis touts effectiveness, safety of autoimmune drug copies
Yahoo/Reuters
Novartis
biosimilars
JNJ
Remicade
Amgen
Enbrel
autoimmune disease
Flag link:
FIRALIS has developed BIOPRED panel to better target inflammatory autoimmune diseases
FIRALIS has developed BIOPRED panel to better target inflammatory autoimmune diseases
CP Wire
Firalis
MRNA
Biopred Immuno-Inflammatory panel
RNA profiling
autoimmune disease
R&D
personalized medicine
Flag link:
FIRALIS has developed BIOPRED panel to better target inflammatory autoimmune diseases
Firalis
MRNA
Biopred Immuno-Inflammatory panel
RNA profiling
autoimmune disease
R&D
Flag link:
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Endpoints
Eli Lilly
Merck KGaA
Btk inhibitors
autoimmune disease
evobrutinib
Flag link:
AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug
AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug
Fierce Biotech
AstraZeneca
autoimmune disease
Viela Bio
spinoffs
biotech
Flag link:
Here's Where Things Went Wrong for Celgene Corporation in 2017
Here's Where Things Went Wrong for Celgene Corporation in 2017
Motley Fool
Celgene
Otezla
autoimmune disease
R&D
Revlimid
Flag link:
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions
Science
cancer
checkpoint inhibitors
autoimmune disease
type 1 diabetes
Flag link:
Merck strikes autoimmune deal with newly-emerged Cue
Merck strikes autoimmune deal with newly-emerged Cue
BioPharma Dive
Merck
autoimmune disease
Cue Biopharma
R&D
drug development
Flag link:
J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease
J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease
Endpoints
JNJ
Ionis Pharmaceuticals
autoimmune disease
IONIS-JBI2-2.5Rx
antisense
Flag link:
Novartis strengthens autoimmune indications for Cosentyx
Novartis strengthens autoimmune indications for Cosentyx
PM Live
Novartis
Cosentyx
autoimmune disease
psoriatic arthritis
ankylosing spondylitis
Flag link:
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Motley Fool
Big Pharma
viral hepatitis
respiratory disease
autoimmune disease
cardiovascular disease
pain
diabetes
cancer
Flag link:
Horizon CEO Tim Walbert knows patients because he is one
Horizon CEO Tim Walbert knows patients because he is one
Medical Marketing and Media
Tim Walbert
Horizon Pharma
Pharma CEOs
autoimmune disease
Duexis
patients
Flag link:
Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
Endpoints
Eli Lilly
autoimmune disease
NKTR-358
Nektar
Flag link:
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
Flag link:
Inside the small Norwood biotech that's making investors swoon
Inside the small Norwood biotech that's making investors swoon
Bizjournals.com
Corbus Pharmaceuticals
autoimmune disease
Flag link:

Pages